Advertisement
GILD vs NVS
Which Stock Would AI Choose? Gilead Sciences (GILD) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Gilead Sciences (GILD) focuses on HIV therapies and oncology, with upcoming second-quarter earnings anticipated to show a significant year-over-year earnings per share (EPS) decline amid broader franchise resilience.
- Novartis (NVS) reported a strong second-quarter 2026 EPS beat of $2.41 versus estimates of $2.16, reaffirming full-year guidance and advancing its pipeline.
- Over recent weeks, NVS has demonstrated stronger year-to-date momentum with gains near 16-17%, compared to more modest or range-bound performance for GILD trading around $130.
- Both companies operate in the biopharmaceutical sector with defensive characteristics, though NVS exhibits lower beta and consistent sales growth drivers.
- Relative positioning highlights trade-offs between GILD’s acquisition activity and pipeline catalysts versus NVS’s recent earnings outperformance and stability.
- Market sentiment reflects earnings timing, with GILD facing near-term scrutiny and NVS benefiting from positive quarterly results.
Introduction
Investors and traders often compare large-cap biopharmaceutical stocks like Gilead Sciences (GILD) and Novartis (NVS) to assess relative value, momentum, and risk within the healthcare sector. This analysis examines their business models, recent price behavior, and market positioning in the current environment. Portfolio managers seeking defensive exposure, growth-oriented investors monitoring pipeline developments, and quantitative traders evaluating trend consistency may find the comparison relevant for allocation decisions or hedging strategies.
GILD Overview and Recent Performance
Gilead Sciences develops and commercializes therapies primarily in HIV, oncology, and inflammation. In recent market activity, the stock has traded in a range near $130, reflecting mixed sentiment ahead of its second-quarter 2026 earnings release scheduled for August 4. Analysts project a notable year-over-year EPS decline for the period, though the company maintains strength in its core HIV franchise and has pursued acquisitions to bolster growth. Broader performance over recent weeks has shown resilience amid sector volatility, with a 52-week range spanning approximately $108 to $157. Factors influencing sentiment include upcoming results and ongoing pipeline advancements in oncology.
NVS Overview and Recent Performance
Novartis operates as a global biopharmaceutical company with a diversified portfolio spanning oncology, cardiovascular, and neuroscience. The stock has delivered solid year-to-date gains of approximately 16-17% as of late July 2026, closing near $156 following its second-quarter results on July 21. Novartis reported an EPS beat of $2.41 against estimates of $2.16 and reaffirmed full-year guidance, supported by sales growth and pipeline progress. In recent weeks, the shares have exhibited relative stability with modest positive returns, trading below their 52-week high near $170 while maintaining defensive characteristics typical of large-cap pharma equities.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, consistent performance metrics, and suitable risk profiles earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with statistics including win rates, drawdowns, and return profiles that vary widely depending on the model. Readers interested in exploring these automated strategies can review the curated list for potential integration into their own market analysis.
Head-to-Head Comparison
Gilead Sciences (GILD) and Novartis (NVS) differ markedly in recent momentum and earnings dynamics. NVS has posted stronger year-to-date returns and delivered an earnings beat with reaffirmed guidance, while GILD approaches its quarterly report amid expectations of an EPS contraction. Business models contrast through GILD’s concentration in HIV and targeted oncology versus NVS’s broader therapeutic diversification. Risk factors include regulatory and clinical trial outcomes for both, though NVS has shown lower volatility in recent periods. Sector exposure remains similar within healthcare, yet sentiment tilts toward NVS following positive quarterly updates compared to pre-earnings positioning for GILD.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, momentum trends, and relative stability, Tickeron’s AI models would likely assign a higher probabilistic preference to NVS in the current environment. The stock’s demonstrated EPS outperformance and year-to-date gains provide a clearer trend signal compared to GILD’s upcoming earnings uncertainty. This assessment reflects pattern recognition rather than certainty and remains subject to new data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and NVS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- GILD’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- GILD’s TA Score: 5 bullish, 6 bearish.
- NVS’s TA Score: 5 bullish, 3 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а +0.70% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.11%. For the same industry, the average monthly price growth was -5.50%, and the average quarterly price growth was +0.63%.
Reported Earning Dates
GILD is expected to report earnings on Aug 04, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.11% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GILD | NVS | GILD / NVS | |
| Capitalization | 162B | 298B | 54% |
| EBITDA | 14.5B | 22.5B | 64% |
| Gain YTD | 7.390 | 16.682 | 44% |
| P/E Ratio | 17.72 | 23.59 | 75% |
| Revenue | 29.7B | 56.7B | 52% |
| Total Cash | N/A | 7.69B | - |
| Total Debt | 22.2B | 49B | 45% |
GILD | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 20 | 5 | |
SMR RATING 1..100 | 24 | 34 | |
PRICE GROWTH RATING 1..100 | 50 | 45 | |
P/E GROWTH RATING 1..100 | 78 | 20 | |
SEASONALITY SCORE 1..100 | n/a | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (8) in the Pharmaceuticals Major industry is in the same range as GILD (9) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
NVS's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as GILD (20) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
GILD's SMR Rating (24) in the Biotechnology industry is in the same range as NVS (34) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.
NVS's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as GILD (50) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
NVS's P/E Growth Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (78) in the Biotechnology industry. This means that NVS’s stock grew somewhat faster than GILD’s over the last 12 months.
| GILD | NVS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 59% | N/A |
| Stochastic ODDS (%) | 4 days ago 55% | 4 days ago 43% |
| Momentum ODDS (%) | 4 days ago 48% | 4 days ago 49% |
| MACD ODDS (%) | 4 days ago 40% | 4 days ago 51% |
| TrendWeek ODDS (%) | 4 days ago 60% | 4 days ago 53% |
| TrendMonth ODDS (%) | 4 days ago 62% | 4 days ago 39% |
| Advances ODDS (%) | 7 days ago 61% | 7 days ago 52% |
| Declines ODDS (%) | 4 days ago 49% | 4 days ago 45% |
| BollingerBands ODDS (%) | 4 days ago 46% | 4 days ago 30% |
| Aroon ODDS (%) | 4 days ago 57% | 4 days ago 49% |
Advertisement